UK markets close in 3 hours 5 minutes

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.5200-0.2200 (-8.03%)
At close: 04:00PM EDT
2.4900 -0.03 (-1.19%)
Pre-market: 08:21AM EDT

AC Immune SA

Building B
EPFL Innovation Park
Lausanne 1015
41 21 345 91 21

Full-time employees133

Key executives

NameTitlePayExercisedYear born
Dr. Andrea Pfeifer Ph.D.Co-Founder, CEO & Director1.09MN/A1957
Mr. Christopher RobertsCFO & VP of FinanceN/AN/A1990
Mr. Piergiorgio DonatiChief Technical Operations OfficerN/AN/A1971
Mr. Jean-Fabien MoninChief Administrative OfficerN/AN/A1971
Mr. Howard DonovanChief HR OfficerN/AN/A1976
Ms. Madiha DerouaziChief Scientific OfficerN/AN/A1973
Dr. Gary Anthony Waanders Ph.D.Senior VP of Investor Relations & Corporate CommunicationsN/AN/A1964
Mr. Alexandre CaratschGeneral CounselN/AN/A1966
Mr. Julian SnowVP of U.S. Finance & Corporate DevelopmentN/AN/AN/A
Dr. David T. HickmanHead of AD - SMEN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Corporate governance

AC Immune SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.